e-TNS Targeted Neuromodulation
Primary headaches, such as migraine, are transmitted by the supraorbital nerve and the supratrochlear nerve. HeadaTerm introduces precise electric impulses from the user’s forehead to act on these nerves and reduce the migraine signals transmitted. The device avoids any drug effects, making it appropriate a wide range of users.
Reference
1. Hokenek N M, Erdogan M O, Hokenek U D, et al. Treatment of migraine attacks by transcutaneous electrical nerve stimulation in emergency department: A randomize controlled trial[J]. The American Journal of Emergency Medicine, 2021, 39: 80-85.
2. Kuruvilla, D.E., Mann, J.I., Tepper, S.J. et al. Phase 3 randomized, double-blind, sham-controlled Trial of e-TNS for the Acute treatment of Migraine (TEAM). Sci Rep 12, 5110 (2022). https://doi.org/10.1038/s41598-022-09071-6
3. Sluka KA, Walsh D. Transcutaneous electrical nerve stimulation: basic science mechanisms and clinical effectiveness. J Pain. 2003 Apr;4(3):109-21.
4. Shealy CN. Transcutaneous electrical nerve stimulation: the treatment of choice for pain and depression. J Altern Complement Med. 2003 Oct;9(5):619-23.
5. Huang W, Kutner N, Bliwise DL. Autonomic activation in insomnia: the case for acupuncture. J Clin Sleep Med. 2011 Feb 15;7(1):95-102.
6. Kirsch DL, Nichols F. Cranial electrotherapy stimulation for treatment of anxiety, depression, and insomnia. Psychiatr Clin North Am. 2013 Mar;36(1):169-76.
7. Schoenen J, Vandersmissen B, Jeangette S, et al. Migraine prevention with a supraorbital transcutaneous stimulator: a randomized controlled trial. Neurology. 2013 Feb 19;80(8):697-704.